EUVIMEDEUVIMED entdecken
Crossref

Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China

Shiyun Lv, Yun Lan iD, Yaozu He, Quanmin Li, Xuemei Ling, Junbin Li, Liya Li iD, Pengle Guo, Fengyu Hu, Weiping Cai, Xiaoping Tang, Jingliang Chen und 1 weitere

Journal of Medical Virology · 2024-10 · 96 (10)

DOI: 10.1002/jmv.29937 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 25.09.2024. Verfasst von Shiyun Lv und 12 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Medical Research Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: HIV Infections, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Project, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The presence of pretreatment drug resistance (PDR) is posing an increasing threat to HIV control. Here we investigated drug resistance mutations (DRMs) and PDR among 6831 HIV‐infected individuals from 2018 to 2022 in Guangzhou, China. DRMs were detected among 24.5% of the patients. The overall prevalence of PDR was 7.4%, with resistance rate to nucleotide reverse transcriptase inhibitor (NRTI) being 1.3%, nonnucleoside reverse transcriptase inhibitor (NNRTI) 4.8%, and protease inhibitor (PI) 1.4%. Abacavir (0.8%) resistance was the most common in NRTI, followed by resistance to emtricitabine (0.6%), lamivudine (0.6%), and tenofovir disoproxil fumarate (0.3%). In NNRTI, nevirapine (3.7%) resistance was the most common, followed by efavirenz (3.5%) and rilpivirine (3.4%). Among PI, resistance to tipranavir (0.8%), nelfinavir (0.6%), fosamprenavir (0.2%) and lopinavir (0.1%) was most frequent. Annual prevalence of PDR showed an increase trend from 2018 to 2022, although not significant. In the multivariable logistic regression model, hepatitis B surface antigen positivity, circulating recombinant form (CRF) 55_01B, CRF08_BC, CRF59_01B, and subtype B were demonstrated as associated risk factors for PDR. The overall prevalence of PDR in Guangzhou was moderate, with relatively severe NNRTI resistance. Therefore, it remains crucial to continue monitoring PDR among newly diagnosed HIV‐infected individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsDrug Resistance, ViralAnti-HIV AgentsHumansChinaMaleAdultFemaleMiddle AgedPrevalenceHIV-1Young AdultMutationReverse Transcriptase InhibitorsAgedAdolescent

Stichwörter der Autor:innen

HIVantiretroviral therapypretreatment drug resistancesubtype

Substanzen

Anti-HIV AgentsReverse Transcriptase Inhibitors

Autor:innen und Institutionen

  • Guangzhou Medical Research Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Infectious Disease Center, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
  • Guangdong Diagnosis and Treatment Quality Control Center of AIDS and Hepatitis C, Guangzhou, China.

ORCID-Profile: Yun Lan, Liya Li, Linghua Li

Förderung

  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Guangzhou Municipal Science and Technology Project
  • National Natural Science Foundation of China
  • Medical Key Discipline Program of Guangzhou-Viral Infectious Diseases

Zitieren

APA

Lv, S., Lan, Y., He, Y., Li, Q., Ling, X., Li, J., Li, L., Guo, P., Hu, F., Cai, W., Tang, X., Chen, J., & Li, L. (2024). Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China. Journal of Medical Virology, 96(10). https://doi.org/10.1002/jmv.29937

Vancouver

Lv S, Lan Y, He Y, Li Q, Ling X, Li J, et al. Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China. Journal of Medical Virology. 2024;96(10). doi:10.1002/jmv.29937

BibTeX
@article{Lv2024,
  author = {Lv, Shiyun and Lan, Yun and He, Yaozu and Li, Quanmin and Ling, Xuemei and Li, Junbin and Li, Liya and Guo, Pengle and Hu, Fengyu and Cai, Weiping and Tang, Xiaoping and Chen, Jingliang and Li, Linghua},
  title = {Pretreatment drug resistance among people living with HIV from 2018 to 2022 in Guangzhou, China},
  journal = {Journal of Medical Virology},
  year = {2024},
  volume = {96},
  number = {10},
  doi = {10.1002/jmv.29937}
}
Kostenlos starten →